www.33psb.com_www.11sbc.com-【最新北京注册网】

来源:175小钢炮让矮个们看到希望!亚当斯被换不冤  作者:   发表时间:2019-05-23 05:18:21

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”About | Our People | Mike Thien, Ph.D.#标题分割#InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

编辑:www.33psb.com_www.11sbc.com-【最新北京注册网】

未经授权许可,不得转载或镜像
© Copyright © 1997-2017 by xuewendong.com all rights reserved

百站百胜: 美军拟在日部署新两栖舰当地民众忧“卷入战争” 新车货架|消费升级的证明超/豪华SUV细分市场已成必… 遭鲍云质疑节目中作弊?戚薇发文回怼:拿出实锤 国米续约未来队长年薪300万欧元续约至2023年 詹姆斯1球再创生涯纪录!这数据他只排历史第19 借壳上市被否后传音转战科创板手机占非洲市场48.7% 北村匠海小松菜奈吉沢亮共演电影演绎兄妹情缘 从天上到地下没有中国人不吃的?我差点就信了 阿尔法·罗密欧GTV设计图曝光将搭混动系统 恒大拿下队史联赛最佳开局!卡帅做到里皮所不能 勇士禁赛贝尔真相曝光!买了一根15美刀的蜡烛 中铝国际2018年度少赚46.6%派息每10股0.3… 进击中的方大集团:5亿入主中兴商业持4家上市公司 东京火炬传递开跑倒计时一年火炬手海选将开始 中国孤独症患者可能超千万0-14岁患者或超200万 教育部规范中小学招生严禁以高额物质奖励揽生源 茅台营销体制悄然生变背后:部分经销商资格被取消 字节跳动投资人发生变更新增高级副总裁张利东 李玟老实认44岁冻龄靠科技自曝曾失声有舞台恐惧 新东方在线联席CEO发内部信:让技术成为发展引擎 内蒙古发生持枪杀人案5人死亡 健力宝原副总外逃17年归案当年的窝案是怎么回事儿? 道明证券预计里拉下个月再次崩盘到5月1日将贬值29% 四部委出台新能源汽车财政补贴新政行业影响几何? 2019超美水燈節即將來襲!不容錯過~ 0-2后无人生还!深圳青年军能否绝地求生? 零壹空间回应火箭发射失利:因箭上速率陀螺出现故障 相爱相杀的房价上涨与消费扩张 国泰航空收购海航旗下香港快运握香港市场超8成份额 消费疲软通胀偏低数据显示美经济正失去动力 零壹空间OS-M首型运载火箭发射失败一级分离后失控 尤文续约年轻中卫至2023年:本赛季要举起欧冠奖杯 曝博格巴今夏想离开曼联!渴望去皇马尤文也想挖 柯文哲:若白绿没分手“韩流”如今不会这么厉害 为什么发达国家工资涨不上去? 一季度全球并购活动下滑17%英退欧不确定性拖累欧洲 海航董事长陈峰回应质疑:欲望把我们推向了快车道 6个撕裂腹肌的动作2个月在家虐出马甲线! 丢人!北京狂扔32三分进4个方硕8中1不是最惨 卡戴珊流泪痛哭怒斥TT出轨感觉TT可能还爱她 银河国际:维持中兴通讯买入评级目标价25.9元 一文看懂破产法司法解释三对借款及财产处置等新规定 索帅谈买人:曼联很有钱但我们绝对不当冤大头 苏媒:江苏节奏始终慢广东一步次节崩盘是败笔 《读者》原董事长被提起公诉:巨额财产来源不明 外媒:叙利亚防空部队击落多枚以色列来袭导弹 应急部回应消防新制服“火焰蓝”色:体现职业责任 尼克斯6连败后锁定“前三”!14%概率喜提锡安 中超-埃尔克森赛季首球艾哈制胜上港2-1客胜华夏 臀腿塑形6个动作在家练助你提臀瘦腿练出好身材 Lyft5年内能盈利吗?彭博和两位创始人聊了聊 中石化油服H股跟涨10.87%A股涨停板 游戏大国被逆袭日媒:中国手游给日企出了道难题 “去美元化”催生“淘金热”俄罗斯推高国际金价 5米大空位不投传库里!唐斯都看不下去了 VIC发布做空特斯拉报告:特斯拉是升级版“庞氏骗局” 二十多天骗七千余万元诈骗团伙准备转战国外被端 印度首射反卫星导弹水平如何?射程再增2倍才能实战 曝锡安只想去骑士打球他要追随詹姆斯的脚步 海马汽车景柱:电动汽车不可能完全取代传统汽车 苹果公司全球副总裁葛越:苹果不把用户的数据货币化 猝不及防!主营“凉”了的盈方微要“戴帽” 中国教育学会办全国学术科研大赛?教育部:冒用 英国无协议脱欧或成默认选项欧盟为此已做好准备 王金平谈2020:我会走到明年1月11日 盼望着盼望着,波士頓的春天終於來了 贝莱德:中国经济企稳今年亚洲美元债回报率上看8% 在加拿大遭绑架中国留学生获救细节:差一点哭出来 上汽通用3品牌39款车型同步调价最高降2.5万元 西部首轮5种对阵猜想:火雷再大战勇士遇强敌 第18届世界警察和消防员运动会将亮相成都 AT&T下周开售MagicLeapOne能和权游… 冰壶世锦赛巴德鑫替补难救主中国负日本两连败 iPhone7终于登陆印度市场6和6s或将被撤出市… 美国警告土耳其:你选俄罗斯不跟你玩了 IHSMarkit:2018年智能手表显示屏出货量同… 单欢欢:体能越踢越好国奥自己打好了谁也不怕 中国恒大纯利升逾五成股价现跌3% 收益率曲线倒挂:这个经济衰退的先行指标可靠吗? 巴菲特:急需帮助的人应得到照顾这是富裕国家的义务 忍着胃痛游出世界最好成绩徐嘉余为什么不开心? 倪光南:大数据是宝贵财富应注意隐私保护和制度完善 国际泳坛频频上演殇离别孙杨一番话为何引深思? 古天乐自称肠胃好拍戏可以一天不吃东西 索尼确认北京工厂3月底停产称中国市场地位不会改变 苹果可能在3月25日发布会上发布iOS游戏订阅服务 3月黑猫投诉企业红黑榜:网贷投诉激增占据黑榜 物管股有追捧佳兆业物业升逾5.04%绿城服务涨约3% 美空军部长:国会若再不批维修资金F22将无家可归 这个\"袖珍大国\"不愿撤出小小高地美对此一反常态 杨幂公开体重仅47.48公斤,竟与两年前一样! 为什么多数健身房都禁止男性裸露上半身? 上海复旦本周六放榜现升近7%兼破顶 英国《金融时报》:亚洲世纪即将到来 特朗普提名的联储理事:美联储应该立即降息50基点 美军派侦察机全程监视印度反卫星并否认是间谍行为 贾秀全高调透露女足世界杯目标:说冠军大家别吓到 李婷宜自曝怀孕时胖到80公斤曾错过演《还珠》 一点资讯法定代表人变更:李亚卸任杨宇翔接任CEO Airwallex宣布完成1亿美元C轮融资DSTG… 口袋理财:因被调查暂无法正常运营即日起暂停发标 英国重要投票前英镑如何走?分析师:技术面强烈看涨 坚定看空美元!摩根士丹利:美元年内要跌6% 扎克伯格的这封公开信堪称教科书级的求生欲了 2019年一季度股市谁哭谁笑?赢家输家一目了然 卡塔尔赛王曼昱30分钟横扫丁宁第二局曾10-0领先 英国汽车产量连降9个月:若无协议脱欧将难以生存 加警方继续调查中国留学生遭绑架案受害人协助调查 性感女教练身材火辣男学员爆满 物管股有资金追捧彩生活飙逾7%新城悦升近4% 陈婷晒照为张艺谋庆生儿子老爸齐对镜甜笑超有爱 特朗普“通俄门”调查过关但这场大戏还没有结束 51岁周涛近照曝光网友:像20岁的小姑娘 马思纯蜡像揭幕谈合作娄烨体验特别 大佬2.38亿美元买豪宅将曼哈顿一季平均房价推高5% 余静萍为卢凯彤办展魏如萱悼念泪流不止 “这些专业对不起良心”高校四百余个专业被撤销 阿里巴巴证实全资收购协作软件平台Teambition 贝佐斯不再孤独,盖茨晋升千亿美元富豪 优酷起诉百度“袋鼠遥控”涉侵权百度败诉赔偿30万 补贴退坡、盈利承压:比亚迪转型面临“阵痛期” 72岁郑少秋近照风度翩翩不显老,网友却在讨论他戴了40… 中国恒大多元化布局已经成型核心净利增逾九成 皇马成抬价工具?曝巴黎开4000万年薪强留姆巴佩 广东福建局地有暴雨西北等地多沙尘 暴力小生来袭奥迪SQ2官图静态解析 小蓝后摩拜也涨价:起步1元骑行每超15分钟加收0.5… 著名恐怖片导演去世曾为《狙击电话亭》写剧本 本季最佳队友入围名单:一哥海王领衔12人名单 互联网行业“吃青春饭”但总有什么能对抗衰老 翼龙在国外突然失联当外军要寻残骸时自己飞回着陆 全新一代本田飞度假想图曝光2019年秋季发布 白敬亭要鞋不要女友?井柏然斩钉截铁被本尊打脸 卡塔尔赛昕雯联播组合进八强许昕:第三局有失误 全球最慷慨的非美国籍亿万富豪了解一下 澳洲央行维持利率不变在政府预算公布前出言谨慎 韦德用了16年终于打败诺天王!红字逼死强迫症 众泰i-across设计图发布上海车展首发 退出与奈飞亚马逊混战!媒体称Youtube取消原创计划 中国足球小“北漂”:下一个梅西?下一个自己 响水爆炸工厂年初查出37项问题2010年曾发生爆炸 海南网信办扫黄打非办约谈天涯:传播色情低俗信息 行走的意义,就在于繁华看尽后,让心灵重归自由 马斯克:特斯拉所有库存汽车将涨价约3% 网约车第一股Lyft上市首日开涨21%市值达253亿… 剑桥校长:接受中国高考成绩不是“抢生源” 翟晓川23+9顾全18分深圳胜北京创历史总分2-2 从盈利变化看A股:下滑仍继续牛市还需进一步验证 直击|马化腾:5G和AI双核驱动下各行业门槛正在降低 时间磨去了年少轻狂,岁月沉淀了冷暖自知 宝宝决定妈妈泌乳量 《欲望都市》将拍续作讲述50岁女人的爱与友谊 英镑兑美元跌破1.3梅的脱欧协议第三次遭议会否决 韩国出口连续四月下滑因芯片降价和中国需求放缓 武大赏樱被打小伙:我爱国没穿和服中国人不能打中国人 名宿:范加尔的风格是曼联最差穆帅也比他好得多 捐款一半资产高达8位数人民币?林志玲泄天价身家 起亚考虑在华停产部分车型工厂向电动化转型 NBA球员工会:强奸案指控我们支持波尔津吉斯 ofo破产?运营主体拜克洛克首次现身全国破产信息网 有望大涨40%,为什么分析师依然不推荐买入特斯拉? 孙正义:曾有机会收购亚马逊30%股份因差钱错失良机 黄金、矿机、虚拟币\"中国大妈\"血泪投资记 医院招募“粪便”捐献者医生:用于重建肠道菌群治疗 日向坂46出道单曲发售更新历代第一周销量记录 新能源汽车补贴退坡利于行业“去芜存菁” 0.1秒绝杀啊!一人单挑四大巨头!他才20岁啊 蒙牛乳业现升近2%暂为最佳蓝筹去年多赚48.6% 美式助学贷:读完大学欠下一屁股债到60多岁还没还完 拉斐尔深夜手写致歉信:只想把球破坏向田依浓道歉 看武磊不用熬夜!西甲照顾中国球迷改比赛时间 埃航空难的黑匣子显示:波音的系统压低了飞机机头 邓紫棋回应蜂鸟起诉强硬喊话:绝不退缩,法庭见 沃尔沃品牌首款纯电动车型XC40年底推出 卡帅:郜林广州塔都有小伤今年比赛投入强于去年 特朗普“戈兰宣言”后真主党呼吁将抵抗到底 向佐求婚郭碧婷?工作人员确认:水到渠成的事情 直击|朱民:三个外生变量为AI发展提供波澜壮阔的舞台 乌兹主帅确认受伤球员缺席两月很多机会没踢进去 又伤一个!有毒啊!康利脚踝扭伤返回更衣室 东风日产新款逍客消息将于4月8日正式上市 口袋理财:因被调查暂无法正常运营即日起暂停发标 皇马PK巴萨抢欧洲两大红星德甲神锋+金童铁卫 英超-越位球扳平悍将91分钟绝杀切尔西2-1险胜 业内人士:别再炒作楼市“小阳春”了 外资评级机构加速入华:这轮想要更多中资机构难抗衡 央行新规:ATM机转账可实时到账,不用再等24小时 美債殖利率倒掛受矚目 法人建議先觀察VIX指數走勢 被曝整容打瘦脸针黄晓明Angelababy夫妇胜诉获… 全球央行外汇储备选择:美元失宠,人民币占比创新高 大V议国奥晋级:过程真让人糟心东京奥运会?做梦! 赵睿26分阿联20+10广东3-0横扫肯帝亚晋级4强 夫妻关系再好,这件事也不能告诉对方 盛世大联突然中止港股上市“见异思迁”要上科创板? 熬最晚的夜,蹦最野的迪!夜太長,跟着老司機玩轉紐約最酷… “小”数据意外抢走恐怖数据风头今日还有一件大事 外媒称戴姆勒拟向吉利出售Smart一半股权